1 Min Read
Dec 27 (Reuters) - Protalix Biotherapeutics Inc :
* Protalix Biotherapeutics receives confirmation of order for over $24 million of Alfataliglicerase to treat gaucher patients in Brazil Source text for Eikon: Further company coverage:
All quotes delayed a minimum of 15 minutes. See here for a complete list of exchanges and delays.
© 2017 Reuters. All Rights Reserved.